N30 Pharma Announces Financing and Addition to Board
Published: May 12, 2010
Joining the Company's Board of Directors will be Dr. Howard Furst of Deerfield Management.
"I am pleased with this successful financing. It will provide resources to move our first drug, N6022 into human testing, as well as support the development of other novel new drugs from our discovery and development platform. In addition, Dr. Furst brings a wealth of healthcare investment and medical expertise to our Board," commented Charles Scoggin MD, CEO of N30.
About N30 Pharma N30 Pharma is a clinical-stage company developing s-nitrosothiol (SNO)-based therapies for major unmet needs in respiratory, cardiovascular, and inflammatory diseases. N30 drugs target s-nitrosoglutathione reductase (GSNOR), the only druggable enzyme that consumes s-nitrosoglutathione (GSNO), a central regulator of the endogenous nitric oxide pool. GSNO, and other SNO's are important modulators of inflammation as well as airway and vascular smooth muscle. N30 is a privately held company headquartered in Boulder, Colorado.
SOURCE N30 Pharmaceuticals